Category: Federal Forum Posters
Purpose: Clozapine is a second-generation antipsychotic approved by the Food and Drug Administration (FDA) for use in patients with schizophrenia. It is currently identified as a treatment option for treatment resistant schizophrenia in both VA policies and national society guidelines. Despite evidence of efficacy and guideline recommendations, clozapine is widely underutilized. A recent study found that only 4% of patients with a schizophrenia diagnosis are prescribed clozapine within the VA Health Care System. A variety of potential barriers to prescribing including intensive monitoring requirements, potential for severe adverse drug reactions, and concern for patient compliance have been identified in the literature.
Methods: Primary outcomes are to assess provider perceived barriers to clozapine prescribing, assess provider opinions of potential interventions to facilitate clozapine prescribing, assess provider knowledge regarding clozapine, and to assess the impact of medication management clinics on clozapine prescribing. Secondary outcomes include comparison of clozapine prescribing rates among providers with different credentials, with or without an academic affiliation, with varying amounts of direct patient care time, with varying levels of comfort and familiarity with clozapine, with different levels of baseline clozapine knowledge, and among different geographic regions. This study will be conducted as a national survey of mental health providers with a scope of practice allowing clozapine prescribing. Any provider in a solely administrative practice role will be excluded. The survey will be conducted utilizing RedCap software and will be sent out as a link using internal VA listserv groups. Weekly reminders will be sent out during the study period to maximize participation. Descriptive statistics will be used when reporting results of the survey. To compare ordinal data from the Likert scale the Mann-Whitney U test will be used. Any nominal data will be compared using a chi-square test. For all objectives, α of < 0.05 will be considered significant.
Results: Not applicable.
Conclusion: Not applicable.
Breanna Moody– Pharmacy Resident, Lexington VA Medical Center, Lexington, KY